Last reviewed · How we verify
oxycodone prolonged release tablet
At a glance
| Generic name | oxycodone prolonged release tablet |
|---|---|
| Sponsor | Mundipharma Research GmbH & Co KG |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102) (PHASE1)
- Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section (PHASE4)
- Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain (PHASE3)
- Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty (NA)
- Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain (PHASE4)
- Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain (PHASE3)
- OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients (PHASE1)
- The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: